Top Markets
#1 Zora Zora +38.60%
#2 Seeker Seeker +23.58%
#3 AI XOVIA AI XOVIA +23.13%
#4 Axelar Axelar +21.86%
#5 Full Moon Full Moon +18.72%
#6 0G 0G +16.10%
#7 Notcoin Notcoin +13.08%
#8 rsERG rsERG +10.68%
#9 VVS Finance VVS Finance +10.41%
#10 Cryptopia Cryptopia +10.26%
Coin of the day
Zora Zora
Settings
Language
ENGLISH
Currency
USD
Theme
Equasens S.A. Equasens S.A.

Equasens S.A.

EQS
Rank in Stocks #12342
Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy,... Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their networks with advanced management systems, including LGPI global services and OffiCentral. Pharmacists leverage a comprehensive suite of tools designed to streamline daily business operations, such as OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker. To foster stronger customer relationships and engagement, Equasens provides innovative solutions like OffiTag, OffiTouch, OffiMédia, OffiConnect, alongside automation systems and loyalty program management. Beyond operational software, the company offers analytical insights through its My Pilot tool and professional development opportunities via OffiLearning, an e-learning platform. A key area of focus is patient support, with offerings spanning compliance monitoring software, Multimeds, Automeds, OffiTéléconsult, and essential pharmaceutical and shared medical record services. The company's specialized systems include ULTIMATE, which combines efficient pharmacy administration with enhanced patient care, and FARMACLICK, a protocol facilitating communication between pharmacies and wholesale distributors (the latter also served by DIFARM). Additional retail management tools comprise PHARE and the SOPHIA pharmacy application, complemented by OffiMédia POS displays. Equasens also addresses specific health needs, such as chronic renal failure management with eNephro, and simplifies the administration of patient education programs through TPE Pilot. Further extending its reach across the healthcare sector, Equasens offers various dedicated solutions like NOVIACARE, CARELIB (for home and nursing home care), KAPELSE, TITAN, ANTHADINE software, the MOBISOINS mobile tool, MICROSOINS for in-home nursing care, and LOGICLIC. For holistic patient journey oversight, the AXIGATE solutions and CHORUS platform are available. Supplementary services include medical telesecretarial assistance for healthcare professionals and equipment lease financing options. Equasens S.A. functions as a subsidiary of Marque Verte Sante.
Share Price
$39.62
Last synced: 2026-08-28
Market Cap
$595.54M
Change (1 day)
0.60%
Change (1 year)
-25.89%
Country
FR
Trade Equasens S.A. (EQS)

Category

Technology
P/E ratio for Equasens S.A. (EQS)
P/E ratio as of 2026 TTM: 0
According to Equasens S.A. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Equasens S.A. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
SAP SE SAP SE
SAP SE
SAP.DE
 27.13 -
DE
Salesforce, Inc. Salesforce, Inc.
Salesforce, Inc.
CRM.US
 22.63 -
US
Shopify Inc. Shopify Inc.
Shopify Inc.
SHOP.TO
 - -
CA
Uber Technologies, Inc. Uber Technologies, Inc.
Uber Technologies, Inc.
UBER.US
 16.40 -
US
ServiceNow, Inc. ServiceNow, Inc.
ServiceNow, Inc.
NOW.US
 77.02 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.